Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Carregando...
Imagem de Miniatura
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
GRANDO, Aline Vitali
FERREIRA, Paulo Roberto Abrao
BRANDAO-MELLO, Carlos Eduardo
REUTER, Tania
MARTINELLI, Ana de Lourdes Candolo
GONZALEZ, Mario Peribanez
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.59, article ID UNSP e67, 8p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-3.83; p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups.
Palavras-chave
Hepatitis C, Chronic hepatitis C, Coinfection HCV-HIV, Interferons, Ribavirin, HCV genotypes
Referências
  1. Adeyemi OM, 2007, J CLIN GASTROENTEROL, V41, P75, DOI 10.1097/01.mcg.0000225592.16448.f3
  2. Ampuero J, 2014, ALIMENT PHARM THER, V39, P686, DOI 10.1111/apt.12646
  3. Ampuero J, 2015, GASTROENTEROL CLIN N, V44, P845, DOI 10.1016/j.gtc.2015.07.009
  4. Bota Simona, 2013, World J Hepatol, V5, P120, DOI 10.4254/wjh.v5.i3.120
  5. Brandao A B, 2001, Rev Panam Salud Publica, V9, P161
  6. Brasil. Ministerio da Saude, 2015, PROT CLIN DIR TER HE
  7. Brasil. Ministerio da Saude, 2016, MAN TECN DIAGN INF P
  8. Buti M, 2015, J VIRAL HEPATITIS, V22, P683, DOI 10.1111/jvh.12419
  9. Buti M, 2015, EXPERT REV GASTROENT, V9, P375, DOI 10.1586/17474124.2015.960396
  10. Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
  11. Cheetham TC, 2015, J MANAG CARE SPEC PH, V21, P641
  12. Chung RT, 2015, HEPATOLOGY, V62, P932, DOI 10.1002/hep.27950
  13. European Ass Study Liver, 2017, J HEPATOL, V66, P153
  14. Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
  15. Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
  16. Hanouneh IA, 2008, CLIN GASTROENTEROL H, V6, P584, DOI 10.1016/j.cgh.2008.02.034
  17. Hauser G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005642.pub3
  18. Karageorgopoulos Drosos E, 2015, World J Hepatol, V7, P1936, DOI 10.4254/wjh.v7.i15.1936
  19. Leroy V, 2016, HEPATOLOGY, V63, P1430, DOI 10.1002/hep.28473
  20. Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
  21. Marcellin P, 2012, HEPATOLOGY, V56, P2039, DOI 10.1002/hep.25892
  22. Messina JP, 2015, HEPATOLOGY, V61, P77, DOI 10.1002/hep.27259
  23. Monje-Agudo P, 2015, EUR J CLIN MICROBIOL, V34, P1929, DOI 10.1007/s10096-015-2434-6
  24. Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726
  25. Rumi MG, 2010, GASTROENTEROLOGY, V138, P108, DOI 10.1053/j.gastro.2009.08.071
  26. Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
  27. Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119
  28. Wright TL, 2002, HEPATOLOGY, V36, pS185, DOI 10.1053/jhep.2002.36812
  29. Zanaga LP, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165504